Revenue
$143.32K
Fiscal year ended 2019-12-31Operating income
-$517.96K
Fiscal year ended 2019-12-31Free cash flow
Unavailable
Fiscal year ended 2019-12-31Sigyn Therapeutics, Inc. (SIGY) reported revenue of $143.32K and net income of -$3.07M for the fiscal year ended 2019-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Sigyn Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Revenue | $143.32K | $28.35K | $38.43K | $29.21K | $43.15K |
| Cost of revenue | $35.66K | $9.71K | $21.43K | $9.93K | $25.25K |
| Gross profit | $107.66K | $18.64K | $17.00K | $19.28K | $17.90K |
| Operating income | -$517.96K | -$1.00M | -$2.03M | -$2.25M | -$387.54K |
| Net income | -$3.07M | -$2.62M | -$4.25M | -$2.69M | -$387.54K |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 81.27M | shares 65.07M | shares 47.09M | shares 30.99M | shares 27.95M |
| Pretax income | -$3.31M | -$2.30M | -$3.84M | -$2.69M | -$387.54K |
| Income tax expense | Unavailable | $800 | $800 | Unavailable | Unavailable |
| Diluted EPS | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $613.78K | $862.41K | $1.05M | $833.55K | $399.88K |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Cash & equivalents | $500 | $7.50K | $9.59K | $638.82K | $95 |
| Total assets | $0 | $862.05K | $2.07M | $1.43M | $562.27K |
| Current assets | $588.61K | $733.19K | $760.55K | $1.16M | $483.80K |
| Total liabilities | $910 | $4.58M | $4.16M | $1.51M | $462.84K |
| Current liabilities | $910 | $4.58M | $4.16M | $1.50M | $462.84K |
| Total equity incl. NCI | -$910 | -$3.72M | -$2.09M | -$82.01K | $99.43K |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $588.11K | $723.60K | $726.14K | $509.79K | $422.51K |
| Accounts receivable | Unavailable | Unavailable | $9.73K | Unavailable | $9.43K |
| Goodwill | Unavailable | Unavailable | $481.95K | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $910 | $22.71K | $72.58K | $20.00K | Unavailable |
Cash flow
| Metric | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Operating cash flow | -$143.68K | -$286.11K | -$400.00K | Unavailable | Unavailable |
| Capital expenditures | Unavailable | $2.95K | $940 | $2.45K | $3.46K |
| Investing cash flow | $100.00K | -$8.45K | -$79.07K | Unavailable | Unavailable |
| Financing cash flow | $36.69K | $292.47K | $339.06K | Unavailable | Unavailable |
| Net change in cash | -$7.00K | -$2.10K | -$140.02K | $638.73K | $95 |
| Stock-based compensation | Unavailable | $114.98K | $919.57K | Unavailable | Unavailable |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Free cash flow | Unavailable | -$289.06K | -$400.94K | Unavailable | Unavailable |
| Gross margin | 75.1% | 65.7% | 44.2% | 66.0% | 41.5% |
| Operating margin | -361.4% | -3544.2% | -5277.4% | -7714.3% | -898.0% |
| FCF margin | Unavailable | -1019.7% | -1043.2% | Unavailable | Unavailable |
| SBC / revenue | Unavailable | 405.6% | 2392.6% | Unavailable | Unavailable |
| Current ratio | Unavailable | 0.16x | 0.18x | 0.78x | 1.05x |
| Revenue YoY growth | 405.6% | -26.2% | Unavailable | -32.3% | Unavailable |
| Net margin | -2145.3% | -9243.2% | -11061.2% | -9224.9% | -898.0% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | 10.4% | 2.4% | 8.4% | 8.0% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SIGY in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-09-05View SEC filing
10-Q · Filed 2025-05-20View SEC filing
10-K · Filed 2025-04-15View SEC filing
10-Q · Filed 2024-11-19View SEC filing
10-Q · Filed 2024-08-19View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.